Natus Medical Announces First Quarter 2022 Financial Results

Rhea-AI Summary

Natus Medical (NASDAQ:NTUS) reported Q1 2022 revenue of $119.8 million, a 4.2% increase from Q1 2021. Operating cash flow reached $8.9 million. GAAP EPS was $0.06, down from $0.07 in the previous year, while non-GAAP EPS rose to $0.22 from $0.16. The company faced over $3.4 million in extraordinary supply chain costs. Natus also announced plans to be acquired by ArchiMed for approximately $1.2 billion, with shareholders set to receive $33.50 per share. The transaction is expected to finalize in Q3 2022, leading to the suspension of financial guidance.

Positive

• Revenue increased 4.2% YoY to $119.8 million.
• Non-GAAP EPS rose to $0.22, up from $0.16 in Q1 2021.
• Core product areas showed strong growth: Brain (6.0%), Neural Pathways (8.7%), and Sensory Nervous Systems (6.0%).
• Acquisition agreement with ArchiMed valued at approximately $1.2 billion.

Negative

• GAAP EPS decreased to $0.06 from $0.07 YoY.
• GAAP gross margin fell to 54.6% from 57.9% in Q1 2021.
• Extraordinary supply chain costs of over $3.4 million were incurred.

	Q1-2022			Key Results
Revenue (millions)	$119.8			• Total revenue increased 4.2% compared to Q1 2021 • Generated $8.9 million in operating cash flow
GAAP EPS	$0.06
Non-GAAP EPS	$0.22

MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months ended March 31, 2022.

For the first quarter ended March 31, 2022, the Company reported revenue of $119.8 million, an increase of 4.2% compared to $114.9 million reported for the first quarter of 2021. GAAP gross margin was 54.6% during the first quarter of 2022 compared to 57.9% in the first quarter of 2021. GAAP net income was $1.9 million, or $0.06 earnings per diluted share, compared with GAAP net income of $2.4 million, or $0.07 earnings per diluted share in the first quarter of 2021.

Non-GAAP gross margin was 56.7% in the first quarter of 2022 compared to 59.6% reported for the first quarter of 2021. Non-GAAP earnings per diluted share was $0.22 for the first quarter of 2022, compared to $0.16 in the first quarter of 2021. Non-GAAP net income was $7.7 million in the first quarter of 2022 compared to $5.4 million in the first quarter of 2021.

“I would like to thank our Natus Teammates for their continued efforts to ensure our products were available to clinicians in the first quarter driving growth despite challenges from both Covid and supply chain related constraints” said Thomas J. Sullivan, President and Chief Executive Officer of Natus. “We incurred over $3.4 million in extraordinary supply chain costs in the quarter consistent with our expectations.”

“We are pleased with the first quarter revenue growth versus year ago in our core areas of clinical focus with Brain, Neural Pathways, and eight Sensory Nervous Systems growing 6.0%, 8.7%, and 6.0% respectively.” “We are also encouraged by the 9.3% revenue growth in supplies and service in these product areas,” concluded Mr. Sullivan.

On April 18, 2022 the Company announced that it entered into a definitive agreement to be acquired by an affiliate of ArchiMed for approximately $1.2 billion. Under the terms of the agreement, Natus shareholders will receive $33.50 in cash for each share of Natus common stock. Under the terms of the merger agreement, Natus may solicit proposals from third parties for a period of 30 days continuing through May 17, 2022, and in certain cases for a period of 35 days continuing through May 22, 2022. The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions, including approval by Natus shareholders and receipt of regulatory approvals. Due to the announced transaction, the Company will no longer update financial guidance.

Use of Non-GAAP Financial Measures

The Company presents in this release its non-GAAP net income, non-GAAP earnings per diluted share, non-GAAP gross margin and non-GAAP operating margin results which exclude amortization expense associated with certain acquisition-related intangibles, restructuring charges, certain discrete items, direct costs of acquisitions, and the related tax effects. A reconciliation between non-GAAP and GAAP financial measures is included in this press release.

The Company believes that the presentation of results excluding these charges or gains provides meaningful supplemental information to both management and investors that is indicative of the Company's core operating results and better reflects the ongoing economics of the Company's operations. The Company believes these non-GAAP financial measures facilitate comparison of operating results across reporting periods.

Specifically, the Company excludes the following charges, gains, and their related tax effects in the calculation of non-GAAP net income, non-GAAP earnings per diluted share and non-GAAP operating profit: 1) Non-cash amortization expense associated with certain acquisition-related intangibles. The charges reflect an estimate of the cost of acquired intangible assets over their estimated useful lives. 2) Restructuring and other non-recurring charges. The Company has over time completed multiple acquisitions of other companies and businesses. Following an acquisition, the Company will, as it determines appropriate, initiate restructuring events to eliminate redundant costs. Restructuring expenses, which are excluded in the non-GAAP items, are exclusively related to permanent reductions in our workforce and redundant facility closures. 3) Certain discrete items. These items represent significant infrequent charges or gains that management believes should be viewed outside of normal operating results, and each significant discrete transaction is evaluated to determine whether it should be excluded from non-GAAP reporting. These items are specifically identified when they occur. 4) Direct costs of acquisitions. These are direct acquisition-related costs that occur when the Company makes an acquisition, such as professional fees, due diligence costs, and earn-out adjustments.

The Company applies GAAP methodologies in computing its non-GAAP tax provision by determining the annual expected effective tax rate after taking into account items excluded for non-GAAP financial reporting purposes.  The Company’s non-GAAP tax expense and its non-GAAP effective tax rate are generally higher than its GAAP tax expense and GAAP effective tax rate because the income subject to taxes would be higher due to the effect of the expenses excluded from non-GAAP financial reporting. The nature of each quarterly discrete transaction will be evaluated to determine whether it should be excluded from non-GAAP reporting.

The Company's management uses these non-GAAP financial measures in assessing the Company's performance and when planning, forecasting, and analyzing future periods and the Company believes that investors also benefit from being able to refer to these non-GAAP financial measures along with the GAAP operating results. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated.

About Natus Medical Incorporated

Natus delivers innovative and trusted solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems to advance the standard of care and improve patient outcomes and quality of life. The Company offers hardware, advanced software and algorithms, and consumables that provide stimulus, acquire and monitor physiological signals, and capture the body’s response. With sales in over 100 countries, Natus is a leader in neurodiagnostics, pediatric retinal imaging, and infant hearing screening, as well as a leading company in hearing assessment, hearing instrument fitting, balance, and intracranial pressure monitoring.

Additional information about Natus Medical can be found at www.natus.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “should,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements in this communication include, but are not limited to, current estimates and assumptions of Natus management as of the date of this press release, statements about the benefits and effects of the merger with ArchiMed (the “transaction”), the expected timing of the completion of the transaction and the amounts to be received by Natus' shareholders. Each forward-looking statement contained in this communication is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, supply chain delays and constraints; the ability of Natus to realize the anticipated benefits from its strategic alignment; Natus' ability to successfully pursue, acquire and integrate acquisitions; the demand for Natus products and services; the impact of adverse global economic conditions and changing governmental regulations, including foreign exchange rate changes, on Natus' target markets; Natus' ability to expand its sales in international markets; Natus' ability to maintain current sales levels in a mature domestic market; Natus' ability to control costs, risks associated with bringing new products to market; Natus' ability to fulfill product orders on a timely basis; the risks related to Ukraine conflict or the COVID-19 pandemic on the global economy and financial markets; the uncertainties relating to the impact of the Ukraine conflict or the COVID-19 pandemic on Natus' business; the uncertainties as to the timing of the transaction; uncertainties as to whether Natus shareholders will approve the transaction; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction, or the terms of such approval; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, vendors and other business partners; the risk that shareholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; other business effects, including the effects of industry, economic or political conditions outside of the parties' control; operating costs and business disruption following completion of the transaction, including adverse effects on employee retention and on Natus' business relationships with third parties; transaction costs; and the risks identified under the heading “Risk Factors” in Natus' Annual Report on Form 10-K, filed with the SEC on February 25, 2022, as well as Natus' subsequent Current Reports on Form 8-K and other information filed by Natus with the SEC. Please consult these documents for a more complete understanding of these risks and uncertainties. This list of factors is not intended to be exhaustive. Such forward-looking statements only speak as of the date of these materials, and Natus assumes no obligation to update any written or oral forward-looking statement made by Natus or on its behalf as a result of new information, future events or other factors, except as required by law.

Additional Information and Where to Find It

This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to the proposed transaction involving Natus. In connection with the proposed transaction, Natus plans to file with the SEC a proxy statement on Schedule 14A (the “Proxy Statement”). This communication is not a substitute for the Proxy Statement or any other document that Natus may file with the SEC and send to its shareholders in connection with the proposed transaction. The proposed transaction will be submitted to Natus' shareholders for their consideration. Before making any voting decision, Natus' shareholders are urged to read all relevant documents filed or to be filed with the SEC, including the Proxy Statement, as well as any amendments or supplements to those documents, when they become available, because they will contain important information about Natus and the proposed transaction.

Natus' shareholders will be able to obtain a free copy of the Proxy Statement, as well as other filings containing information about Natus, free of charge, at the SEC's website (www.sec.gov). Copies of the Proxy Statement and other documents filed by Natus with the SEC may be obtained, without charge, by contacting Natus through its www.natus.com under the heading Investor Relations.

Participants in the Solicitation

The Company, its directors, executive officers and other persons related to Natus may be deemed to be participants in the solicitation of proxies from Natus’ shareholders in connection with the proposed transaction. Information about the directors and executive officers of Natus and their ownership of Natus common stock is set forth in Natus’ annual report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 25, 2022 and in its proxy statement for its 2022 annual meeting of stockholders, which was filed with the SEC on April 28, 2022. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Proxy Statement and other relevant materials to be filed with the SEC in connection with the proposed transaction when they become available. Free copies of these documents may be obtained as described in the preceding paragraph.

Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com        

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited)
(in thousands, except per share amounts)
	Three Months Ended
	March 31, 2022				March 31, 2021
Revenue	$	119,793			$	114,927
Cost of revenue		52,781				46,688
Intangibles amortization		1,600				1,751
Gross profit		65,412				66,488
Gross profit margin		54.6	%			57.9	%
Operating expenses:
Marketing and selling		29,551				28,971
Research and development		13,224				14,040
General and administrative		12,807				14,855
Intangibles amortization		3,598				3,897
Restructuring		2,051				205
Total operating expenses		61,231				61,968
Income from operations		4,181				4,520
Interest expense		(267	)			(766	)
Other expense, net		(540	)			(890	)
Income before provision for income tax		3,374				2,864
Provision for income tax1		1,471				468
Net income	$	1,903			$	2,396
Net income per share:
Basic	$	0.06			$	0.07
Diluted	$	0.06			$	0.07
Weighted-average shares:
Basic		34,119				33,611
Diluted		34,276				33,782
1The increase in the effective tax rate for the three months ended March 31, 2022 compared with the three months ended March 31, 2021, is primarily attributable to a tax law change in effect from January 1, 2022 that requires the capitalization of research and experimental costs under IRC Section 174. The approximate impact of the change in the estimated tax rate due to all impacts from IRC Section 174 resulted in a $0.01 reduction in the GAAP earnings per share.

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands)
	March 31,			December 31,
	2022			2021
ASSETS
Current assets:
Cash and investments	$	84,285		$	75,595
Accounts receivable		103,714			111,760
Inventories		72,238			67,745
Other current assets		26,531			22,191
Total current assets		286,768			277,291
Property and equipment		21,391			21,783
Operating lease right-of-use assets		8,027			9,288
Goodwill and intangible assets		208,119			214,170
Deferred income tax		23,548			23,161
Other assets		20,230			18,595
Total assets	$	568,083		$	564,288
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	34,342		$	36,405
Accrued liabilities		47,185			48,135
Deferred revenue		26,846			25,097
Current portion of operating lease liabilities		4,482			4,964
Total current liabilities		112,855			114,601
Deferred income tax		1,451			1,133
Long-term operating lease liabilities		5,755			6,567
Other long-term liabilities		17,128			17,237
Total liabilities		137,189			139,538
Total stockholders’ equity		430,894			424,750
Total liabilities and stockholders’ equity	$	568,083		$	564,288

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
(in thousands)
	Three Months Ended
	March 31, 2022				March 31, 2021
Operating activities:
Net income	$	1,903			$	2,396
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for losses on accounts receivable		87				101
Depreciation and amortization		6,673				7,257
Loss on equity method investment		192				136
Loss on disposal of property and equipment		30				8
Warranty reserve		1,363				341
Share-based compensation		2,619				3,114
Loss on commencement of sales-type leases		—				6
Changes in operating assets and liabilities:
Accounts receivable		8,803				4,962
Inventories		(6,132	)			4,139
Prepaid expenses and other assets		(4,752	)			(4,028	)
Accounts payable		(1,957	)			1,303
Accrued liabilities		(1,762	)			1,172
Deferred revenue		1,949				2,732
Deferred income tax		(119	)			1,064
Net cash provided by operating activities		8,897				24,703
Investing activities:
Purchase of property and equipment		(1,062	)			(731	)
Purchase of equity method investments		(572	)			—
Net cash used in investing activities		(1,634	)			(731	)
Financing activities:
Proceeds from stock option exercises and ESPP		4,191				—
Taxes paid related to settlement of equity awards		(1,228	)			(1,150	)
Principal payments of financing lease liability		(447	)			(125	)
Payments on borrowings		—				(20,000	)
Net cash provided by (used in) financing activities		2,516				(21,275	)
Exchange rate changes effect on cash and cash equivalents		(1,089	)			(4,230	)
Net increase (decrease) in cash and cash equivalents		8,690				(1,533	)
Cash and cash equivalents, beginning of period		75,595				82,082
Cash and cash equivalents, end of period	$	84,285			$	80,549

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited)
(in thousands, except per share amounts)
	Three Months Ended
	March 31, 2022			March 31, 2021
GAAP based results:
Income before provision for income tax	$	3,374		$	2,864
Non-GAAP adjustments:
Intangibles amortization (COGS)		1,600			1,751
Restructuring and other non-recurring costs (COGS)		905			611
COVID-19 relief (COGS)		—			(402	)
Intangibles amortization (OPEX)		3,598			3,897
Direct costs of acquisitions (OPEX)		—			21
Restructuring and other non-recurring costs (OPEX)		2,497			579
COVID-19 relief (OPEX)		—			(2,512	)
Non-GAAP income before provision for income tax		11,974			6,809
Income tax expense, as adjusted1	$	4,312		$	1,397
Non-GAAP net income	$	7,662		$	5,412
Non-GAAP earnings per share:
Basic	$	0.22		$	0.16
Diluted	$	0.22		$	0.16
Weighted-average shares used to compute
Basic non-GAAP earnings per share		34,119			33,611
Diluted non-GAAP earnings per share		34,276			33,782
1The increase in the effective tax rate for the three months ended March 31, 2022 compared with the three months ended March 31, 2021, is primarily attributable to a tax law change in effect from January 1, 2022 that requires the capitalization of research and experimental costs under IRC Section 174. The approximate impact of the change in the estimated tax rate due to all impacts from IRC Section 174 resulted in a $0.03 reduction in the non-GAAP earnings per share.

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited)
(in thousands, except per share amounts)
	Three Months Ended
	March 31, 2022				March 31, 2021
GAAP Gross Profit	$	65,412			$	66,488
Amortization of intangibles		1,600				1,751
COVID-19 relief		—				(402	)
Restructuring and other non-recurring costs		905				611
Non-GAAP Gross Profit	$	67,917			$	68,448
Non-GAAP Gross Margin		56.7	%			59.6	%
GAAP Operating Income	$	4,181			$	4,520
Amortization of intangibles		5,198				5,648
COVID-19 relief		—				(2,914	)
Restructuring and other non-recurring costs		3,402				1,190
Direct cost of acquisitions		—				21
Non-GAAP Operating Income	$	12,781			$	8,465
Non-GAAP Operating Margin		10.7	%			7.4	%
GAAP Income Tax Expense	$	1,471			$	468
Effect of accumulated change of pretax income		3,608				1,006
Effect of change in annual expected tax rate		(767	)			(77	)
Non-GAAP Income Tax Expense	$	4,312			$	1,397

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
GROSS MARGIN BY END MARKETS (unaudited)
(in thousands)
	Three Months Ended
	March 31, 2022				March 31, 2021
Brain:
Revenue	$	51,388			$	48,484
Cost of revenue		20,392				17,219
Intangibles amortization		512				533
Gross profit	$	30,484			$	30,732
Gross profit margin		59.3	%			63.4	%
Neural Pathways:
Revenue	$	19,392			$	17,840
Cost of revenue		9,533				8,047
Intangibles amortization		203				210
Gross profit	$	9,656			$	9,583
Gross profit margin		49.8	%			53.7	%
Sensory Nervous Systems:
Revenue	$	37,673			$	35,532
Cost of revenue		16,789				14,702
Intangibles amortization		851				951
Gross profit	$	20,033			$	19,879
Gross profit margin		53.2	%			55.9	%
Other:
Revenue	$	11,340			$	13,071
Cost of revenue		6,067				6,720
Intangibles amortization		34				57
Gross profit	$	5,239			$	6,294
Gross profit margin		46.2	%			48.2	%
Consolidated:
Revenue	$	119,793			$	114,927
Cost of revenue		52,781				46,688
Intangibles amortization		1,600				1,751
Gross profit		65,412				66,488
Gross profit margin		54.6	%			57.9	%

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP GROSS MARGIN BY END MARKETS
(unaudited)
(in thousands)
	Three Months Ended
	March 31, 2022				March 31, 2021
Brain:
GAAP Gross Profit	$	30,484			$	30,732
Amortization of intangibles		512				533
COVID-19 relief		—				(83	)
Restructuring and other non-recurring costs		278				211
Non-GAAP Gross Profit	$	31,274			$	31,393
Non-GAAP Gross Margin		60.9	%			64.7	%
Neural Pathways:
GAAP Gross Profit	$	9,656			$	9,583
Amortization of intangibles		203				210
COVID-19 relief		—				(33	)
Restructuring and other non-recurring costs		105				80
Non-GAAP Gross Profit	$	9,964			$	9,840
Non-GAAP Gross Margin		51.4	%			55.2	%
Sensory Nervous Systems:
GAAP Gross Profit	$	20,033			$	19,879
Amortization of intangibles		851				951
COVID-19 relief		—				(280	)
Restructuring and other non-recurring costs		408				242
Non-GAAP Gross Profit	$	21,292			$	20,792
Non-GAAP Gross Margin		56.5	%			58.5	%
Other:
GAAP Gross Profit	$	5,239			$	6,294
Amortization of intangibles		34				57
COVID-19 relief		—				(6	)
Restructuring and other non-recurring costs		114				78
Non-GAAP Gross Profit	$	5,387			$	6,423
Non-GAAP Gross Margin		47.5	%			49.1	%
Consolidated:
GAAP Gross Profit	$	65,412			$	66,488
Amortization of intangibles		1,600				1,751
COVID-19 relief		—				(402	)
Restructuring and other non-recurring costs		905				611
Non-GAAP Gross Profit	$	67,917			$	68,448
Non-GAAP Gross Margin		56.7	%			59.6	%

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
GEOGRAPHIC REVENUE (unaudited)
(in thousands)
	Three Months Ended
	March 31, 2022				March 31, 2021
Consolidated Revenue:
United States	$	69.97			$	67,772
International		49.823				47,155
Totals	$	119.793			$	114,927
United States		58	%			59	%
International		42	%			41	%
Totals		100	%			100	%

 

FAQ

What were Natus Medical's Q1 2022 earnings results?

Natus Medical reported revenue of $119.8 million, GAAP EPS of $0.06, and non-GAAP EPS of $0.22 for Q1 2022.

How much did Natus Medical increase its revenue in Q1 2022 compared to Q1 2021?

Natus Medical's revenue increased by 4.2% compared to Q1 2021.

What acquisition deal was announced by Natus Medical?

Natus Medical announced it will be acquired by ArchiMed for approximately $1.2 billion.

What is the expected closing date for the Natus Medical acquisition?

The acquisition is expected to close in the third quarter of 2022.

Did Natus Medical provide financial guidance after the acquisition announcement?

No, Natus Medical will no longer update its financial guidance due to the acquisition.